Comprehensive Notes: Binding Kinetics, Neural Excitability, Glia, and BBB

Saturation binding, specific binding, and binding parameters

• Definitions

  • Total binding (B_total): all ligand bound and unbound considered;
  • Nonspecific binding (B_nonspecific): ligand bound non-selectively to sites other than the receptor of interest;
  • Specific binding (B_specific): the portion of binding due to receptor sites:

  $B<em>{ ext{specific}} = B</em>{ ext{total}} - B_{ ext{nonspecific}}.$

• Saturation binding curve

  • Relationship between specific binding and free ligand concentration [L]:

  $B<em>{ ext{specific}} = B</em>{ ext{max}} \frac{[L]}{K_D + [L]}.$

  • B_max: maximal binding (plateau level as [L] becomes large).
  • K_D: ligand concentration at which half of the receptor sites are occupied.
  • From the transcript: Bmax is estimated from the plateau (e.g., ≈ 5.4 × 10^2 fmol/mg); KD corresponds to the half-saturation point (≈ a few ×10^2 fmol/mg depending on dataset).

• Data interpretation cues from the example

  • Visual: as radiolabeled acetylcholine increases, binding approaches a plateau because there are finite receptor sites.
  • Saturation binding illustrates Bmax and KD visually before formal fitting.
  • Example interpretation notes: the half-saturation point appears around the 2.7–2.8 × 10^2 fmol/mg range; the plateau indicates B_max around the 5.4 × 10^2 fmol/mg region.

• Scatchard (bound/free vs bound) plot for parameter extraction

  • Scatchard relation (B/F vs B):

  $\frac{B}{F} = \frac{B<em>{ ext{max}}}{K</em>D} - \frac{1}{K_D} B.$

  • Here, slope = ext{−}1/KD and x-intercept = Bmax.
  • y-intercept = Bmax/KD.
  • This conversion turns binding data into a straight line from which Bmax and KD can be inferred.

• How to plot data for interpretation

  • To plot binding as Bound/Free vs Bound, compute Bound (fmol/mg) and Free ligand at each concentration.
  • Free ligand calculation requires a units-consistent conversion, see unit-conversion notes below.

• Units and practical conversion notes (example workflow)

  • In the example, volumes and tissue protein concentration are given: assume a reaction volume of 1 mL and tissue protein concentration of 0.2 mg/mL.
  • Unit equivalences used in the example:
  • Picomolar (pM) ≡ picomoles per liter; in a 1 mL volume, 1 pM corresponds to 1 fmol total.
  • Therefore, 1 pM ≡ 1 fmole in 1 mL; when normalized per mg, conversion depends on protein concentration:

  $ext{Bound}<em>{[{ ext{fmol/mL}}]} = B</em>{ ext{bound}} imes [ ext{protein}] = B<em>{ ext{bound}} ext{ (fmol/mg)} imes C</em>{ ext{protein}} ext{ (mg/mL)}.$

  • With a protein concentration of 0.2 mg/mL, 1 fmole/mL corresponds to 5 fmoles/mg; i.e., 1 pM ≈ 5 fmol/mg.
  • Practical calculation steps per concentration
  • Total ligand in fmol/mL: LtotalfmolpermL = ([L] in pM) × (1 fmol/mL per pM at V = 1 mL).
  • BoundfmolpermL = Bboundfmolpermg × Cproteinmgper_mL.
  • FreefmolpermL = LtotalfmolpermL − BoundfmolpermL.
  • Bound/Free = BoundfmolpermL / FreefmolpermL.
  • Example takeaway: you can estimate KD and Bmax directly from the data or from the scatter/line fits, and you can subsequently compute Bound/Free to generate the bound vs. bound plot or perform a regression to obtain KD from the slope.

• Competition binding (Ki) overview and example

  • Definition: Ki is the concentration of a competing drug that inhibits 50% of ligand binding (i.e., knocks off 50% of receptor-ligand complexes).
  • Practical approach (as in the transcript): choose a middle concentration of radioligand (e.g., 500 pM) with known specific binding (e.g., 244 fmol/mg).
  • For each competing drug (e.g., atropine, pilocarpine, oxotremorine), measure the remaining specific binding at various drug concentrations.
  • Convert to percent of total specific binding (divide by the total binding without any drug, 244 fmol/mg, to get % bound).
  • Plot percent bound vs log(concentration of drug).
  • Ki extraction by visual/line-intersection method: draw a horizontal line at 50% bound and drop a perpendicular to the x-axis to read Ki.
  • Reported Ki values from the example (in pM):
  • Atropine: ≈ 79 pM
  • Pilocarpine: ≈ 355 pM
  • Oxotremorine: ≈ 1000 pM
  • Most potent competitor is the drug with the smallest Ki (atropine in the example).

• Practical interpretation and relevance

  • KD reflects affinity of the ligand for its receptor; smaller KD means higher affinity.
  • B_max reflects receptor density (maximum binding capacity).
  • Ki reflects competitive potency of an added drug relative to the radioligand.
  • While Ki and IC50 are related, Ki is adjusted for radioligand occupancy and is often more informative for comparing competitor affinities across assays (via the Cheng-Prusoff correction in general cases).

• Additional notes on the nervous system context (contextual relevance of the above experiments)

  • The experiments described are classical pharmacological tools to quantify receptor-ligand interactions and drug competition, foundational for understanding receptor pharmacology.
  • The concepts of KD, Bmax, and Ki tie directly to receptor theory, ligand binding assays, and drug development for targeting receptors.

Neurons, synapses, and nerve signal transmission

• Neurons and structural diversity

  • Examples of neuron types:
  • Cerebellar Purkinje neuron: single axon, huge dendritic tree, can receive input from ~500,000 other neurons.
  • Spinal motor neuron: cell body in spinal cord; axon projects to muscles; dendrites labeled by MAP2; axon axon initial segment with voltage-gated Na+ channels.
  • Hippocampal pyramidal neuron: cell body with dendrites; axon labeled with tau protein.

• How cells communicate in the nervous system

  • Electrochemical synapses: electrical signal in presynaptic neuron triggers release of chemical neurotransmitters to affect postsynaptic neuron.
  • Presynaptic axon terminals contain synaptic vesicles with neurotransmitter.
  • Synaptic cleft is the narrow gap between presynaptic terminal and postsynaptic membrane; not an empty space due to adhesion molecules.
  • Postsynaptic density: region enriched with receptors on the postsynaptic membrane.
  • Glial involvement: astrocytes located near synapses; astrocytes contribute to neurotransmitter uptake and ion buffering; sometimes interact with neurons at the synapse.

• Synaptic structure and variability

  • A dendritic spine is a protrusion on a dendrite that forms a synapse; a single spine can form multiple synapses with different axon terminals.
  • The synaptic cleft is typically 10–20 nanometers wide; physical adhesion molecules stabilize the synapse.

• Membrane potential basics

  • Resting membrane potential (RMP) is typically around −70 mV.
  • Depolarization and action potential: when the membrane potential crosses a threshold, voltage-gated Na+ channels open, Na+ influx depolarizes the cell, then Na+ channels inactivate and voltage-gated K+ channels open to repolarize.

• Nernst potential and ionic gradients

  • A single ion’s equilibrium potential E_ion is set by the balance of concentration gradient and electrical gradient:

  $E<em>i = \frac{RT}{z</em>i F} \, ext{ln}\left(\frac{[i]<em>{ ext{out}}}{[i]</em>{ ext{in}}}\right).$

  • For potassium (K+), EK ≈ −70 mV; for sodium (Na+), ENa ≈ +60 mV.
  • The resting membrane potential is influenced by selective membrane permeability to K+, Na+, and Cl−; at rest, the membrane is far more permeable to K+ than to Na+, helping keep the RMP near E_K.

• Ion channel gating and membrane dynamics

  • Ion channels opened by voltage changes are responsible for changing membrane permeability to specific ions.
  • If more Na+ channels open (higher Na+ permeability), the membrane potential depolarizes toward ENa; when Na+ channels close and K+ channels open, the membrane repolarizes toward EK.
  • The Na+/K+-ATPase pump maintains ionic gradients by pumping 3 Na+ out and 2 K+ in per ATP hydrolyzed, consuming cellular energy.

• Energy metabolism and ATP production in neurons

  • Neuronal activity is energy-intensive due to ion pumping; ATP is generated primarily via mitochondrial respiration.
  • Key metabolic steps:
  • Glycolysis produces pyruvate, which enters the mitochondria.
  • Citric acid cycle (Krebs cycle) and oxidative phosphorylation generate ATP.
  • Oxygen is required for efficient ATP production; the brain is an energy-intensive organ (~high energy demand relative to mass).

• Membrane resistance and capacitance; myelination

  • Membrane resistance depends on the state of ion channels (open vs closed): more open channels → lower resistance; closed channels → higher resistance.
  • Membrane capacitance depends on membrane area and thickness; larger thickness and proper alignment reduce capacitance.
  • Myelin increases membrane resistance and decreases capacitance, enabling faster conduction (saltatory conduction) by allowing rapid depolarization to jump between nodes of Ranvier.
  • Demyelinating diseases (e.g., multiple sclerosis) impair conduction velocity by reducing myelin integrity and increasing capacitance.

• Action potentials: the basic all-or-none electrical event

  • Threshold depolarization triggers opening of voltage-gated Na+ channels; rapid Na+ influx depolarizes the membrane toward E_Na.
  • Na+ channels rapidly inactivate; voltage-gated K+ channels open later, causing K+ efflux and repolarization.
  • Absolute and relative refractory periods limit firing rate and shape neuronal signaling.

• Temporal and spatial summation as integration mechanisms

  • Temporal summation: rapid successive inputs at the same synapse summate to reach threshold.
  • Spatial summation: simultaneous inputs at multiple synapses on the neuron summate to reach threshold.

• Relevance of channel properties to pharmacology and disease

  • Sodium channels (Na_v): critical for depolarization; drugs that stabilize the inactivated state (e.g., phenytoin, carbamazepine) limit firing rate and reduce hyperexcitability (epilepsy treatment).
  • Potassium channels (K_v): contribute to repolarization and resting potential; delayed rectifier K+ channels contribute to AP repolarization.
  • Calcium channels (Ca_v): voltage-gated; crucial for triggering neurotransmitter release at terminals; multiple subtypes (L, T, P/Q, N, R) with distinct tissue distributions and roles.
  • Calcium influx at presynaptic terminals couples to neurotransmitter release via vesicle fusion.

• Types of voltage-gated calcium channels and drug implications

  • L-type (Cav1.x): important in cardiac and smooth muscle; targets for cardiovascular drugs (calcium channel blockers: verapamil, diltiazem, nifedipine).
  • N-type and P/Q-type (Cav2.x): major contributors to neurotransmitter release in CNS; modulators can affect synaptic transmission.

• Other channel families to know

  • Cyclic nucleotide-gated channels: gated by cAMP/cGMP; important in sensory transduction (e.g., rod photoreceptors).
  • TRP channels: diverse family; involved in sensing temperature, pain, and chemical stimuli (e.g., TRPV1 activated by capsaicin).
  • GABAergic chloride channels: hyperpolarizing receptors that dampen excitability; open Cl− channels to inhibit neuron firing; inhibition can be modulated by various agents (Strychnine blocks glycine receptors, etc.).

• Neurotransmitter receptors and ionotropic channels

  • Ionotropic receptors form ligand-gated ion channels that directly mediate ion flow in response to neurotransmitter binding (e.g., glutamate receptors, GABA_A receptors).
  • Emphasis in the lecture is on voltage-gated channels for excitability, but neurotransmitter receptor channels are also critical for synaptic transmission.

• Glia, synapse remodeling, and brain immune surveillance

  • Astrocytes: GFAP+, support neuron growth and survival, secrete neurotrophic factors (e.g., GDNF); can become pro-inflammatory in disease (reactive astrogliosis).
  • Microglia: resident CNS immune cells; remodel synapses by pruning inactive synapses; can contribute to pathology if overactive.
  • Oligodendrocytes (CNS) and Schwann cells (PNS): myelin-producing cells; MS involves oligodendrocyte loss and demyelination.

• Blood-brain barrier (BBB) basics and drug delivery challenges

  • BBB structure: brain capillaries with tight junctions between endothelial cells, astrocyte endfeet (endfoot processes), and pericytes; tight junctions minimize paracellular diffusion.
  • Endothelial pumps and transporters: P-glycoprotein (P-gp) and MRPs pump foreign substances back into the blood, limiting brain entry.
  • Hypothalamic/pituitary regions have slightly leaky areas to sample systemic blood as part of hormonal and metabolic regulation.
  • Approaches to cross BBB:
  • Prodrugs: attach a lipophilic moiety to improve membrane permeation and later release the active drug in brain tissue.
  • Receptor-mediated transport: exploit transferrin receptor–mediated transcytosis by linking drugs to antibodies against the transferrin receptor; transferrin binds iron, and the complex is transported into the brain.
  • Practical considerations and limitations
  • Drug design must balance lipophilicity, receptor affinity, and transporter interactions to achieve sufficient brain penetration without off-target effects.

• Quick recap of key players and their roles

  • Resting membrane potential: ~−70 mV; largely set by K+ permeability and the K+ equilibrium potential (E_K).
  • Action potential: Na+ influx (depolarization) followed by K+ efflux (repolarization); Na+ channel inactivation is a key target for anti-seizure medications.
  • Energy demands: ATP-dependent pumps maintain gradients; neurons rely on glucose metabolism and mitochondrial respiration with oxygen.
  • Myelination: increases conduction speed via saltatory conduction; demyelination slows or blocks signal transmission.
  • BBB: protects brain from blood-borne toxins; presents a major hurdle for CNS drug delivery; multiple strategies exist to improve brain access.

• Ethical and practical implications

  • Understanding ion channel function and drug interactions informs treatment of epilepsy, hypertension, chronic pain, and neurodegenerative diseases.
  • Interventions to cross the BBB must minimize systemic exposure and off-target effects; targeted delivery strategies aim to enhance CNS selectivity and safety.
  • Glial biology and neuroinflammation are increasingly recognized as central to CNS disease; therapies targeting astrocytes or microglia are active research areas.

• Connections to foundational principles

  • Receptor-ligand binding concepts (KD, Bmax, Ki) connect to pharmacology and receptor theory foundational in biochemistry.
  • Electrophysiology basics (membrane potential, ion gradients, channels) underpin neurophysiology and signal transduction.
  • Energy metabolism links cellular physiology to organismal neuroscience, illustrating how basic biochemistry supports neural function.

• Formulas and equations to remember

  • Specific binding and saturation:
    $B<em>{ ext{specific}} = B</em>{ ext{max}} \frac{[L]}{K_D + [L]}$
  • Ki in competition (conceptual; exact calculation depends on assay):
    $K<em>i = \frac{IC</em>{50}}{1 + [L]/K_D}$
  • Scatchard plot relationship (bound/free vs bound):
    $\frac{B}{F} = \frac{B<em>{ ext{max}}}{K</em>D} - \frac{1}{K_D} B$
  • Spike of neuronal ion selectivity (Nernst equation):
    $E<em>i = \frac{RT}{z</em>i F} \, ext{ln}\biggl(\frac{[i]<em>{ ext{out}}}{[i]</em>{ ext{in}}}\biggr)$
  • Sodium-potassium pump stoichiometry (Na+/K+-ATPase):
    ext{ATP} + 3 \, ext{Na}^+{ ext{in}} + 2 \, ext{K}^+{ ext{out}}
    ightarrow ext{ADP} + ext{Pi} + 3 \, ext{Na}^+{ ext{out}} + 2 \, ext{K}^+_{ ext{in}}